Financial Summary

Reata Pharmaceuticals Inc  (RETA)  $114.02    (%)

  • Symbol
    RETA
    Price
    114.02$
    Beta
    1.65339
    Volume Avrg.
    349935
    Market Cap
    4117923330
    Last Div
    0
    Range
    88.17-257.965
    Changes
    0.18
    Changes Percentage
    Exchange
    NASDAQ Global Market
    Industry
    Biotechnology
    Ceo
    Mr. J. Warren Huff
    Sector
    Healthcare

About company

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.


Income Statement

Year Revenue Cost of revenues Gross profit Operating expensess Operating incomes Interest expense Income tax expenses Earnings before taxs Net income Earnings per share basics Earnings per share diluteds Dividend per shares Gross margins EBIT margins Profit margins EBITDA EBIT Earnings Before Tax Margins Net Profit Margins
2020 274515.00 169559.00 104956.00 38668.00 66288.00 0.00 968.00 67091.00 57411.00 3.31 3.28 0.803333414346 0.382332477278109 0.300289471658 0.209136112780722 77344.00 66288.00 0.244398302460703 0.209136112780722
2019 260174.00 161782.00 98392.00 34462.00 6393.00 3576.00 10481.00 65737.00 55256.00 2.97145 2.97145 3.03705403822 0.378178 0.245720171885 0.212381 8186.00 6393.00 0.252666 0.212381
2018 265595.00 163756.00 101839.00 30941.00 70898.00 324.00 11872.00 72903.00 59531.00 2.97649 2.97649 2.74234021698 0.383437 0.266940266195 0.224142 85546.00 70898.00 0.274489 0.224142
2017 229234.00 141048.00 88186.00 26842.00 61344.00 2323.00 15738.00 64089.00 48351.00 2.3175 2.3025 2.43140686849 0.384698604918991 0.267604282087 0.210924208450753 76569.00 61344.00 0.27957894553164 0.210924208450753
2016 215639.00 131376.00 84263.00 24239.00 60024.00 1456.00 15685.00 61372.00 45687.00 2.07658 2.07658 2.20897805039 0.39076 0.278354101067 0.211868 73333.00 60024.00 0.284605 0.211868
2015 233715.00 140089.00 93626.00 22396.00 7123.00 733.00 19121.00 72515.00 53394.00 2.30422 2.30422 1.99566067658 0.400599 0.304772907173 0.228458 84505.00 7123.00 0.310271 0.228458
2014 182795.00 112258.00 70537.00 18034.00 52503.00 384.00 13973.00 53483.00 3951.00 1.61318 1.61318 1.817183144 0.38588 0.287223392325 0.216144 61813.00 52503.00 0.292585 0.216144
2013 17091.00 106606.00 64304.00 15305.00 48999.00 136.00 13118.00 50155.00 37037.00 1.41969 1.41969 11.338876116 0.376245 0.286694751624 0.216705 57048.00 48999.00 0.293459 0.216705
2012 156508.00 87846.00 68662.00 13421.00 55241.00 1088.00 1403.00 55763.00 41733.00 1.57673 1.57673 2.63181556135 0.438712 0.35295959312 0.266651 60128.00 55241.00 0.356295 0.266651
2011 108249.00 64431.00 43818.00 10028.00 3379.00 519.00 8283.00 34205.00 25922.00 0.98833 0.98833 0.0 0.404789 0.312150689614 0.239466 36538.00 3379.00 0.315984 0.239466
2010 65225.00 39541.00 25684.00 7299.00 18385.00 311.00 4527.00 1854.00 14013.00 0.54121 0.54121 0.0 0.393775 0.281870448448 0.214841 19878.00 18385.00 0.284247 0.214841
2009 42905.00 25683.00 17222.00 5482.00 1174.00 407.00 3831.00 12066.00 8235.00 0.32426 0.32426 0.0 0.401398 0.2812 0.191936 13207.00 12066.00 0.281226 0.191936
Year202020192018201720162015201420132012201120102009
Revenue274515.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues169559.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense0.003576.00324.002323.001456.00733.00384.00136.001088.00519.00311.00407.00
Income tax expenses968.0010481.0011872.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.312.971452.976492.31752.076582.304221.613181.419691.576730.988330.541210.32426
Earnings per share diluteds3.282.971452.976492.30252.076582.304221.613181.419691.576730.988330.541210.32426
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.008186.0085546.0076569.0073333.0084505.0061813.0057048.0060128.0036538.0019878.0013207.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.240.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.210.220.210.210.230.220.220.270.240.210.19